Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Mid Week Watchlist And Other Goodies

**For free weekly 8-12 page granular investment reports on individual small, attractive and underfollowed biotech stocks, just take five seconds to register @ biotechfreereports.com**

Recently I've had several readers express being overwhelmed keeping up with all ideas presented here. Remember THE KEY, especially when one is starting out with a small account, is to focus just on a handful of stories that appeal to you. The big money is made by staying in until the thesis plays out, not trading in and out for a few points of profit.

Current lineup for potential analysis includes but is not limited to:

Benitec Biopharma (NASDAQ:BNTC)

Guidewire Software (NYSE:GWRE)

Paratek Pharmaceuticals (NASDAQ:PRTK)

NewLink Genetics (NASDAQ:NLNK)

Neos Therapeutics (NASDAQ:NEOS)

Intra-Cellular Therapies (NASDAQ:ITCI)

Halozyme Therapeutics (NASDAQ:HALO)

As always my watchlist changes quite a bit, and some or all of above might not make the cut to articles. Any tickers you think should be added representing a near or mid term opportunity?

**Also, stay tuned for my exclusive interview notes from my call with the CEO of Cascadian Therapeutics (NYSE:CASC). I hope in the future to interview one to a few management teams or other important figureheads per month, depending on what my current work schedule permits.

***Don't forget to follow me on Twitter, lots of interesting Wall Street chatter, analyst upgrades and other helpful tidbits posted this week.

**As for my Facebook group, I made the decision going forward to submit one currently undervalued idea for reader discussion that I find attractive. This will help me generate maximum value for followers, as well as avoid filling up your News Feeds with non essential clutter. I get plenty of questions on which former and current ideas are good buys now, so that should help in that regard. Feel free to chime in in comments on what you think of the idea, bear commentary, etc.

Cheers.

Jonathan